American Society of Addiction Medicine

This Week in Addiction Medicine from ASAM

Health EN ↓ 100 episodes

This Week in Addiction Medicine is an audio summary of the recent top stories and research articles from the field of addiction medicine. Intended to serve as an accompaniment to the ASAM Weekly newsletter or as a stand-alone resource, This Week covers recent publications in addiction medicine research.

Author

American Society of Addiction Medicine

Category

Health

Latest episode

Jul 7, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 5M+ downloads · 4.8 rating iOS soon

Episodes

Lead: The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies 17.12.2024

The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies Psychological Medicine Using data from the EU-GEI case-control study and UK Biobank, researchers examined the independent and combined effect of heavy cannabis use and schizophrenia polygenic risk score (PRS), on risk for psychosis. Schizophrenia PRS a...

Lead: Prevalence of pharmacotherapy for attention-deficit/hyperactivity disorder and prescription stimulant misuse: A national study of US college students 10.12.2024

Prevalence of pharmacotherapy for attention-deficit/hyperactivity disorder and prescription stimulant misuse: A national study of US college students Addiction This is an observational study using cross-sectional data from the American College Health Association–National College Health Assessment III. It measured the association between university-level prevalence of attention deficit/hyperactivit...

Lead: Xylazine Pharmacokinetics in Patients Testing Positive for Fentanyl and Xylazine 04.12.2024

Xylazine Pharmacokinetics in Patients Testing Positive for Fentanyl and Xylazine   Clinical Chemistry This study of xylazine pharmacokinetics used plasma samples from 28 patients who had urine screens positive for xylazine and fentanyl. The patients were being treated for skin lesions, most commonly, then shortness of breath or opioid overdose. At least two subsequent plasma samples were analyzed...

Lead: Suicide in people prescribed opioid-agonist therapy in Scotland, United Kingdom, 2011–2020: A national retrospective cohort study 19.11.2024

Suicide in people prescribed opioid-agonist therapy in Scotland, United Kingdom, 2011–2020: A national retrospective cohort study  🔓 Addiction This retrospective cohort study aimed to determine if opioid agonist therapy (OAT) in Scotland is protective against suicide, and measure trends in suicide rates in those with opioid dependence over time. The study included 46,453 individuals who received...

Lead: Links between adolescent binge drinking and midlife alcohol use behaviors by age, sex, and race/ethnicity 05.11.2024

Links between adolescent binge drinking and midlife alcohol use behaviors by age, sex, and race/ethnicity  🔓 Alcohol Clinical and Experimental Research Using data from the Monitoring the Future study, which enrolled cohorts of high school seniors annually starting in 1976, this analysis evaluated alcohol drinking patterns in adults 35-60 and potential association with their drinking patterns at a...

Lead: Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder 29.10.2024

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder JAMA Network This population-based retrospective cohort study assessed whether the use of buprenorphine/naloxone is associated with lower risk of treatment discontinuation and mortality compared with methadone. It included 30,891 individuals initiating treatment for the first time during the study period and found that  t...

Lead: Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization 22.10.2024

Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization  🔓 JAMA Network Open  This cross-sectional study using health care claims data from 35,451 US adults with an opioid use disorder diagnosis assessed whether buprenorphine treatment using doses higher than Food and Drug Administration recommendations is associated with subsequent acute health care utilization. Those rec...

Lead: Facilitators of and barriers to buprenorphine initiation in the emergency department: a scoping review 15.10.2024

Facilitators of and barriers to buprenorphine initiation in the emergency department: a scoping review   The Lancet Regional Health Americas In the context of the opioid overdose epidemic, great efforts have been made to increase access to medication for opioid use disorder (MOUD), specifically buprenorphine. Initiation of buprenorphine in emergency departments (ED) has been a focus of these effor...

Lead: Cannabis Policy Impacts Public Health and Health Equity 08.10.2024

Cannabis Policy Impacts Public Health and Health Equity National Academy of Sciences Engineering Medicine This report from the National Academies of Sciences, Engineering, and Medicine urges the federal government to provide policy guidance to states that have legalized cannabis, close regulatory loopholes on intoxicating products derived from hemp, and create a public health campaign aimed at par...

ASAM Weekly Special Episode: Dr. Shannon Miller talks PAM-7 and his path to addiction medicine [From the ASAM 55th Annual Conference] 30.09.2024

In this episode recorded live at ASAM's 55th Annual Conference in Fort Worth, TX, host Dr. Nick Athanasiou sat down with Dr. Shannon Miller to discuss his work on PAM-7, and his path to addiction medicine.   Subscribe to the ASAM Weekly

Lead: Risk of Incident Psychosis and Mania With Prescription Amphetamines 24.09.2024

Risk of Incident Psychosis and Mania With Prescription Amphetamines The American Journal of Psychiatry This case-control study used electronic health records to examine the impact of dose levels of prescription amphetamines on the risk of incident psychosis and mania with prescription amphetamines. Among 1,374 case subjects and 2,748 control subjects, the odds of psychosis and mania were increased...

Lead: Cannabis Laws and Utilization of Medications for the Treatment of Mental Health Disorders 17.09.2024

Cannabis Laws and Utilization of Medications for the Treatment of Mental Health Disorders   🔓 JAMA Network Open This cross-sectional study of 9,438,716 commercially insured patients examined if access to cannabis, via medical or recreational legalization, is associated with changes in the dispensing of prescription medications to treat mental health disorders. Researchers found statistically sign...

Lead: State-level racial and ethnic disparities in buprenorphine treatment duration in the United States 10.09.2024

State-level racial and ethnic disparities in buprenorphine treatment duration in the United States   The American Journal on Addictions National trends reveal a concerning escalation in racial and ethnic disparities in buprenorphine treatment duration for opioid use disorder. This study examined such disparities at the state level. Analyzing 9,040,620 buprenorphine prescriptions dispensed between...

Lead: Virtual reality-based Mindfulness-Oriented Recovery Enhancement (MORE-VR) as an adjunct to medications for opioid use disorder: a Phase 1 trial 04.09.2024

Virtual reality-based Mindfulness-Oriented Recovery Enhancement (MORE-VR) as an adjunct to medications for opioid use disorder: a Phase 1 trial  🔓 Annals of Medicine Mindfulness-Oriented Recovery Enhancement (MORE) uses mindfulness training to address dysregulation in brain reward systems. MORE has been shown to reduce drug cue reactivity and in an RCT reduced opioid misuse 45% at 9 months. Face-...

Lead: The Lancet Psychiatry Commission on youth mental health 27.08.2024

The Lancet Psychiatry Commission on youth mental health 🔓 The Lancet Psychiatry Mental ill health, which has been the leading health and social issue impacting the lives and futures of young people for decades, has entered a dangerous phase. Accumulating research evidence indicates that in many countries, the mental health of emerging adults has been declining steadily over the past two decades,...

Lead: Alcohol Consumption Patterns and Mortality Among Older Adults With Health-Related or Socioeconomic Risk Factors 20.08.2024

Alcohol Consumption Patterns and Mortality Among Older Adults With Health-Related or Socioeconomic Risk Factors   JAMA Network Open  This British study included 135,103 older (median age 64) adults and compared drinking patterns with mortality during a median follow-up of 12 years. Compared to occasional drinkers, low-risk drinkers had higher cancer mortality (HR, 1.11), moderate-risk drinkers had...

Lead: Physician Reluctance to Intervene in Addiction: A Systematic Review 13.08.2024

Physician Reluctance to Intervene in Addiction: A Systematic Review JAMA Network Open This systematic review of 283 articles explored the reasons physicians give for not addressing substance use and addiction in their clinical practice. The institutional environment (81.2% of articles) was the most common reason given for physicians not intervening in addiction, followed by lack of skill (73.9%),...

ASAM Weekly Special Episode: Rapid Initiation of Injection Naltrexone for OUD | Dr. Matisyahu Shulman & Dr. Adam Bisaga 06.08.2024

Host Dr. Nick Athanasiou sat down with Drs. Matisyahu Shulman and Adam Bisaga to discuss the study they recently authored titled Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Trial. The doctors share their findings and the impact and implications of the study.    Subscribe to The ASAM Weekly to read the guest editorial:  Guest Editorial: Rapid...

Lead: Social Vulnerability and Prevalence and Treatment for Mental Health and Substance Use Disorders 06.08.2024

Social Vulnerability and Prevalence and Treatment for Mental Health and Substance Use Disorders JAMA Psychiatry This is a survey study of 4,674 participants from US households that examined the association between social vulnerability and mental health and substance use disorders and related treatment in the US noninstitutionalized population of adults aged 18 years and older. Large increases in s...

Lead: Psilocybin desynchronizes the human brain 30.07.2024

Psilocybin desynchronizes the human brain   Nature To assess how human brain network changes relate to the subjective and lasting effects of psychedelics, this study tracked individual-specific brain changes with longitudinal precision functional mapping (roughly 18 magnetic resonance imaging visits per participant). Psilocybin massively disrupted functional connectivity (FC) in the cortex and sub...

Lead: Secondhand Nicotine Absorption From E-Cigarette Vapor vs Tobacco Smoke in Children 23.07.2024

Secondhand Nicotine Absorption From E-Cigarette Vapor vs Tobacco Smoke in Children   JAMA Network Open This cross-sectional study of 1,777 US children aged 3 to 11 years examined how children’s nicotine absorption, as indexed by serum cotinine level, differ among those exposed to (1) secondhand tobacco smoke only, (2) secondhand e-cigarette vapor only, or (3) neither. Compared with children expose...

Lead: Benzodiazepine use in relation to long-term dementia risk and imaging markers of neurodegeneration: a population-based study 16.07.2024

Benzodiazepine use in relation to long-term dementia risk and imaging markers of neurodegeneration: a population-based study  🔓 BMC Medicine This study examined the relationship between benzodiazepine (BZD) use and dementia, using data from the population-based Rotterdam (Netherlands) study started in 1990. For 5,443 participants, BZD use during the 15 years from 1990 to 2005 was compared to deme...

Lead: Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial 09.07.2024

Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial   Nature Medicine The safety and tolerability of racemic ketamine may be improved if given orally, as an extended-release tablet (R-107), compared with other routes of administration. In this phase 2 multicenter clinical trial, male and female adult patients with treatment-resistant...

Lead: Global status report on alcohol and health and treatment of substance use disorders 02.07.2024

Global status report on alcohol and health and treatment of substance use disorders World Health Organization This report utilizes data from the WHO member states to summarize alcohol consumption, its health consequences, and alcohol policies around the world. Overall, there was a decrease in alcohol consumption between 2010 and 2019, but alcohol-related deaths still accounted for 4.7% of all deat...

Lead: Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths 25.06.2024

Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths The New England Journal of Medicine  HEALing (Helping to End Addiction Long-term Initiative) Communities Study (HCS) investigators examined the potential of the community-engaged, data-driven Communities That HEAL (CTH) intervention to reduce the rate of opioid-related overdose deaths in highly affected communities. Interven...

Listen to the This Week in Addiction Medicine from ASAM podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.